查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011252

呼吸系統藥物市場：2026年至2032年全球市場預測（依產品類型、給藥途徑、通路、適應症及最終用戶分類）

Pulmonary Drugs Market by Product Type, Route Of Administration, Distribution Channel, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，呼吸系統藥物市場價值將達到 932.5 億美元，到 2026 年將成長至 1,006.8 億美元，到 2032 年將達到 1,613.7 億美元，複合年成長率為 8.14%。

主要市場統計數據
基準年 2025 932.5億美元
預計年份：2026年 1006.8億美元
預測年份 2032 1613.7億美元
複合年成長率 (%) 8.14%

不斷變化的患者需求、日益複雜的監管以及臨床和商業性需求的融合，為呼吸護理領域的創新創造了條件。

呼吸醫學領域正處於一個轉折點，科學突破、不斷變化的患者期​​望和不斷變化的監管要求在此交匯融合。過去十年，生物製藥、醫療設備工程和真實世界數據分析的進步重塑了從氣喘到肺動脈高壓等多種疾病的臨床路徑。隨著醫療服務擴大轉向門診和居家環境，治療效果與以患者為中心的設計之間的相互作用正成為臨床應用的關鍵因素。這些因素共同要求相關人員在藥物發現、臨床開發和商業化的每個階段重新評估優先事項。

突破性的科學進步、數位療法和基於價值的醫療保健模式如何重塑呼吸醫學領域的藥物研發、藥物傳遞和病人參與。

多項變革正在重塑呼吸系統藥物的發現、核准和給藥方式。生物製藥和標靶小分子化合物的出現，拓展了傳統支氣管擴張劑和吸入性皮質類固醇以外的治療選擇，使針對重度氣喘和間質性肺病等多種適應症的個人化治療成為可能。同時，醫療設備的創新，特別是乾粉吸入器、定量吸入器和霧化器的改進，正在彌合藥理學與臨床有效給藥之間的差距。這些技術進步與數位醫療能力的更緊密結合，進一步增強了其應用，例如透過遠端醫療醫療監測用藥依從性並調整治療劑量。

評估 2025 年美國對藥品採購、生產決策和跨境臨床作業徵收關稅的累積經濟和供應鏈影響。

到2025年，美國關稅政策變化帶來的累積影響正將呼吸系統藥物製造商、合約開發商和經銷商的營運複雜性提升到一個新的水平。關稅成本壓力正在影響企業在原料藥採購、契約製造組織（CMO）選擇以及二級包裝業務選址等方面的決策。因此，如今的籌資策略通常需要仔細權衡關鍵地區專業化生產能力和監管合規帶來的益處與關稅風險。這些趨勢也向下蔓延至整個供應鏈，影響庫存計畫、吸入器和預填充式注射器的前置作業時間以及供應商網路冗餘等方面的決策。

從細分市場的觀點揭示了影響呼吸系統藥物採用率和臨床結果差異的產品、給藥途徑、分銷、適應症和最終用戶趨勢。

精細的細分分析揭示了決定產品優先順序的因素，即臨床需求、給藥技術和分銷管道趨勢的交匯點。在考慮產品類型細分時，例如生物製藥、支氣管擴張劑、聯合治療和吸入性皮質類固醇，可以清楚地看到，每個類別對臨床開發和設備相容性都有不同的要求。吸入性皮質類固醇本身可細分為倍氯米松、Budesonide和Fluticasone製劑。每種製劑對製劑穩定性和設備性能都有其獨特的影響，這會影響處方醫生的選擇和患者的依從性。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢影響研究重點、監管途徑、定價談判以及患者獲得呼吸治療的機會。

地理環境影響呼吸系統治療的臨床研發重點、監管策略和商業性模式。在美洲，支付方和醫療服務提供者越來越關注真實世界的臨床結果和成本效益，這促使製造商提供強力的核准後證據並簽訂創新合約。北美監管路徑強調數據透明度和患者報告結果，從而影響對試驗設計和附加檔說明書內容的預期。

策略競爭策略、夥伴關係模式和創新組合，使呼吸系統藥物生態系統中領先的生物製藥和醫療設備公司脫穎而出。

呼吸系統藥物生態系的競爭動態由差異化的產品組合、醫療設備能力和夥伴關係策略決定。主要企業正將治療創新與醫療設備專業知識結合，打造能夠提高病患用藥依從性和治療效果的整合解決方案。而其他企業則採取互補策略，專注於能夠透過有針對性的臨床試驗和精心設計的患者支持計畫來建立臨床差異化的領域。生物製藥研發公司與醫療設備製造商之間的策略聯盟日益普遍，這有助於縮短實用化時間，並增強其在實際應用中的療效。

產業領導者優先採取的策略行動是加速肺部疾病治療產品組合的創新，確保供應鏈的韌性，並最佳化商業模式。

行業領導者應推動一系列優先措施，使科學創新與商業性可行性和營運韌性相契合。首先，應在研發生命週期的早期階段整合醫療設備和製劑的開發，確保吸入性能、病人便利性和監管證據得到並行而非順序的考量。早期協調可降低後期重新設計的風險，並提高產品上市後成功打入市場的可能性。

採用穩健的混合方法，結合臨床證據、相關人員訪談和供應鏈分析，以確保檢驗且經過驗證的見解。

本執行摘要所依據的研究採用了穩健的混合方法，以確保研究結果具有實證性和可操作性。整合臨床證據包括利用同儕審查文獻、指引更新和註冊登記數據，以整體情況各種治療方法並比較與關鍵適應症相關的終點指標。同時，研究人員也與價值鏈上的相關人員——包括臨床研究人員、藥物採納決策者、生產專家和患者權益倡導團體——進行了訪談和結構化討論，從而為理解定量訊號和運營挑戰提供了定性方面的深度資訊。

整合相關人員面臨的策略挑戰，將科學進步轉化為可及、經濟高效且以病人為中心的呼吸照護。

總之，呼吸系統藥物的格局正受到多種因素的共同影響而重塑，這些因素包括科學、醫療設備工程、支付方的期望以及供應鏈的實際情況。積極整合醫療設備和製劑開發、制定穩健的籌資策略並產生令人信服的真實世界數據的相關人員，將更有能力將創新轉化為永續的臨床和商業性成功。著重於產品類型的細分，包括生物製藥、支氣管擴張劑、聯合治療和吸入性皮質類固醇（包括倍氯米松、Budesonide和Fluticasone等亞型），將確保治療方法的設計與實際應用案例和患者需求相符。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 呼吸系統藥物市場：依產品類型分類

  • 生物製藥
  • 支氣管擴張劑
  • 聯合治療
  • 吸入性皮質類固醇
    • 倍氯米松
    • Budesonide
    • Fluticasone

第9章 呼吸系統藥物市場：依給藥途徑分類

  • 吸入
    • 乾粉吸入器
    • 定量吸入器
    • 噴霧器
  • 注射
    • 預填充式注射器
    • 管瓶
  • 口服
    • 膠囊
    • 液體
    • 藥片

第10章 呼吸系統藥物市場：依分銷管道分類

  • 物理藥房
  • 網路藥房

第11章 呼吸系統藥物市場：依適應症分類

  • 氣喘
  • 慢性阻塞性肺病（COPD）
  • 囊腫纖維化
  • 間質性肺病
  • 肺纖維化
  • 肺動脈高壓
  • 呼吸道感染疾病

第12章 呼吸系統藥物市場：依最終用戶分類

  • 門診部
  • 居家醫療
  • 醫院
  • 專科診所

第13章 呼吸系統藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 呼吸系統藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 呼吸系統藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國呼吸系統藥物市場

第17章：中國呼吸系統藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Insmed Incorporated
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma, Inc.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
Product Code: MRR-4316E4E893EF

The Pulmonary Drugs Market was valued at USD 93.25 billion in 2025 and is projected to grow to USD 100.68 billion in 2026, with a CAGR of 8.14%, reaching USD 161.37 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 93.25 billion
Estimated Year [2026] USD 100.68 billion
Forecast Year [2032] USD 161.37 billion
CAGR (%) 8.14%

Setting the stage for pulmonary therapeutics innovation with evolving patient needs, regulatory complexity, and converging clinical and commercial imperatives

The pulmonary therapeutic landscape stands at an inflection point where scientific breakthroughs converge with changing patient expectations and evolving regulatory demands. Over the past decade, advances in biologics, device engineering, and real-world data analytics have reshaped clinical pathways for conditions ranging from asthma to pulmonary hypertension. As care delivery increasingly shifts toward ambulatory and home settings, the interplay between therapy performance and patient-centric design has become a decisive factor in clinical adoption. These forces collectively require stakeholders to reassess priorities across discovery, clinical development, and commercialization.

This executive summary synthesizes critical developments that influence how stakeholders should think about drug design, route of administration, and distribution strategy. It frames the conversation around patient outcomes, operational resilience, and payer acceptance rather than simple transactional metrics. By situating therapeutic choices within the broader context of health system pressures and patient preferences, the introduction sets a pragmatic baseline for the deeper analyses that follow. The aim is to provide leaders with a concise, evidence-oriented perspective to guide near-term decisions while keeping strategic optionality for future innovation.

How disruptive scientific advances, digital therapeutics, and value-based care models are reshaping drug development, delivery, and patient engagement in pulmonary medicine

Several transformative shifts are redefining how pulmonary drugs are discovered, approved, and delivered to patients. Biologic modalities and targeted small molecules are expanding the therapeutic toolkit beyond traditional bronchodilators and inhaled corticosteroids, enabling personalized approaches for heterogeneous indications such as severe asthma and interstitial lung disease. At the same time, device innovation-particularly improvements in dry powder inhalers, metered dose inhalers, and nebulizer systems-is closing the gap between pharmacology and effective real-world delivery. These technological advances are being amplified by stronger integration of digital health capabilities, from adherence monitoring to telemedicine-enabled titration of therapy.

Concurrently, value-based contracting and greater emphasis on long-term clinical outcomes are changing payer and provider behavior. Manufacturers are responding with risk-sharing arrangements, outcomes studies, and more sophisticated health economic evidence packages. Supply chain resilience and onshore manufacturing considerations are also taking center stage, influencing decisions about formulation, packaging, and route-of-administration choices. Together, these shifts demand that companies adopt cross-functional approaches that align R&D, regulatory affairs, manufacturing, and commercial teams around patient-centric evidence and measurable clinical impact.

Assessing the cumulative economic and supply chain consequences of United States tariffs in 2025 on drug sourcing, manufacturing decisions, and cross-border clinical operations

The cumulative effect of tariff policy changes in the United States through 2025 has introduced a new layer of operational complexity for manufacturers, contract developers, and distributors serving pulmonary therapeutics. Tariff-driven cost pressures have influenced where companies source active pharmaceutical ingredients, select contract manufacturing organizations, and locate secondary packaging operations. As a result, procurement strategies now often weigh tariff exposure against the benefits of specialized capacity and regulatory alignment in key geographies. These dynamics reverberate downstream, affecting inventory planning, lead times for inhalers and prefilled syringes, and decisions about redundant supplier networks.

In response, several manufacturers have intensified efforts to diversify supplier bases and to secure near-term inventory buffers for high-dependency components such as specialized inhaler actuators and biologic drug substance. Regulatory submissions and quality oversight have become more complex as global suppliers are evaluated against both compliance and tariff risk profiles. This environment also accelerates conversations about vertical integration for critical steps like device assembly or sterile fill-finish, as organizations seek to reduce exposure to sudden policy shifts. In short, tariff changes have elevated supply chain strategy from a cost-management issue to a core component of clinical program viability and commercial readiness.

Segment-level perspectives that reveal product, administration route, distribution, indication, and end-user dynamics driving differential adoption and clinical outcomes in pulmonary drugs

A nuanced segmentation analysis reveals where clinical need, delivery technology, and channel dynamics intersect to shape product priorities. When considering product type segmentation across biologics, bronchodilators, combination therapies, and inhaled corticosteroids, it is clear that each category imposes distinct requirements for clinical development and device compatibility. Inhaled corticosteroids themselves break down further into beclomethasone, budesonide, and fluticasone variants, each with unique formulation stability and device performance implications that influence prescriber preference and adherence.

Route of administration further differentiates strategy: inhalation modalities including dry powder inhalers, metered dose inhalers, and nebulizers demand close collaboration between formulation scientists and device engineers to optimize deposition and patient usability. Injection options such as prefilled syringes and vials carry their own cold-chain and sterility considerations, while oral forms in capsules, liquids, and tablets present manufacturing scale advantages but different adherence and pharmacokinetic profiles. Distribution channels, split between offline pharmacies and online pharmacies, alter access dynamics and require distinct commercial tactics to reach physicians and patients.

Indication-based segmentation highlights therapeutic complexity across asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, pulmonary hypertension, and respiratory infections; each clinical area prioritizes different endpoints, safety profiles, and patient education needs. Finally, end-user segmentation encompassing ambulatory care centers, homecare settings, hospitals, and specialty clinics underscores the importance of service models and training to achieve optimal therapeutic outcomes. Together, these intersecting segmentations call for integrated product strategies that align formulation, device design, and distribution with clinical pathways and care settings.

Regional dynamics across the Americas, EMEA, and Asia-Pacific that shape research priorities, regulatory pathways, pricing negotiations, and patient access for pulmonary therapies

Geographic context shapes clinical development priorities, regulatory strategy, and commercial approaches in pulmonary therapeutics. In the Americas, payers and providers are increasingly focused on real-world outcomes and cost-effectiveness, pushing manufacturers to produce robust post-approval evidence and to engage in innovative contracting. North American regulatory pathways emphasize data transparency and patient-reported outcomes, which in turn affect trial design and labeling expectations.

Europe, Middle East & Africa presents a mosaic of reimbursement frameworks and health technology assessment approaches that require localized health economic models and adaptable pricing strategies. Regulatory timelines and device approval nuances differ substantially across the region, influencing where biopharma and device firms stage their launches. In Asia-Pacific, rapid adoption of novel therapeutic approaches coexists with diverse regulatory structures and manufacturing ecosystems that favor local partnerships. Stakeholders in this region often prioritize access, localization of supply, and scalable manufacturing, which can accelerate the deployment of device-integrated therapies and generic competition. Across all regions, regional R&D hubs and centers of excellence are emerging as critical nodes for clinical trial execution and post-market surveillance, reinforcing the need for geographically tailored strategies that consider regulatory idiosyncrasies, payer expectations, and patient access pathways.

Strategic competitive behaviors, partnership models, and innovation portfolios that distinguish leading biopharma and device players in the pulmonary drugs ecosystem

Competitive dynamics in the pulmonary drugs ecosystem are defined by differentiated portfolios, device capabilities, and partnership strategies. Leading companies combine therapeutic innovation with device expertise to create integrated solutions that improve adherence and therapeutic outcomes. Others pursue a complementary playbook by focusing on specialty indications where clinical differentiation can be established through targeted trials and curated patient support programs. Strategic alliances between biopharma developers and device manufacturers have become common, enabling faster time-to-use and stronger claims around real-world performance.

Innovation leadership is also contingent on supply chain and manufacturing excellence. Firms that invest in advanced sterile fill-finish, scalable inhalation device assembly, and robust quality systems are better positioned to respond to regulatory scrutiny and to maintain supply continuity during demand spikes. Commercially, companies that cultivate close relationships with payers and key opinion leaders and that support value demonstration through pragmatic clinical studies tend to secure more favorable formulary positioning. Finally, mid-sized and emerging players that excel in nimble R&D and specific clinical niches frequently become attractive partners for larger organizations seeking to expand biologics or device-enabled offerings, underscoring the role of M&A and licensing as ongoing drivers of portfolio renewal.

Priority strategic actions for industry leaders to accelerate innovation, secure resilient supply chains, and optimize commercial models for pulmonary drug portfolios

Industry leaders should pursue a set of prioritized actions that align scientific innovation with commercial viability and operational resilience. First, integrate device and formulation development earlier in the R&D lifecycle to ensure that inhalation performance, patient usability, and regulatory evidence are considered in parallel rather than sequentially. Early alignment reduces late-stage redesign risk and improves the chance of favorable adoption at launch.

Second, diversify supplier networks for critical components and consider selective nearshoring of high-risk manufacturing steps to mitigate tariff and geopolitical exposure. This should be complemented by scenario-driven inventory planning and dual-sourcing strategies for specialized actuators, prefilled syringes, and biologic drug substance. Third, invest in real-world evidence generation and outcomes-based contracts tailored to high-burden indications such as severe asthma and pulmonary hypertension to demonstrate long-term value to payers. Fourth, develop differentiated channel strategies that address the distinct requirements of offline and online pharmacies while ensuring consistent patient support and education across settings. Finally, cultivate partnerships with specialty clinics and homecare providers to accelerate adoption in ambulatory and home settings, and to capture insights that can inform iterative product improvements and post-market safety monitoring.

Robust mixed-methods approach combining clinical evidence synthesis, stakeholder interviews, and supply chain analysis to ensure actionable and validated insights

The research underpinning this executive summary employed a robust mixed-methods approach to ensure findings are evidence-based and actionable. Clinical evidence synthesis drew on peer-reviewed literature, guideline updates, and registries to map therapeutic landscapes and to compare endpoints relevant to key indications. In parallel, interviews and structured discussions with stakeholders across the value chain-clinical investigators, formulary decision-makers, manufacturing experts, and patient advocates-provided qualitative depth that contextualized quantitative signals and operational challenges.

Supply chain analysis included mapping of critical suppliers, assessment of tariff impacts on sourcing decisions, and evaluation of manufacturing options for inhalation devices, sterile injectables, and oral-solid dosage forms. Commercial assessments integrated channel dynamics for offline and online pharmacies and considered patient access barriers across ambulatory care centers, homecare settings, hospitals, and specialty clinics. Throughout the study, methodological rigor was maintained through triangulation of data sources and validation of key findings with independent subject-matter experts, yielding insights that are both practical and defensible for decision-making.

Synthesis of strategic imperatives for stakeholders to translate scientific advances into accessible, cost-effective, and patient-centered pulmonary therapies

In conclusion, the pulmonary drugs landscape is being reshaped by converging forces in science, device engineering, payer expectations, and supply chain realities. Stakeholders who proactively integrate device and formulation development, build resilient sourcing strategies, and generate compelling real-world evidence will be best positioned to translate innovation into sustained clinical and commercial success. Attention to segmentation-across product types such as biologics, bronchodilators, combination therapies, and inhaled corticosteroids with subtypes including beclomethasone, budesonide, and fluticasone-ensures that therapeutic design aligns with real-world use cases and patient needs.

Similarly, deliberate choices about route of administration, whether inhalation via dry powder inhalers, metered dose inhalers, and nebulizers, injection via prefilled syringes and vials, or oral formats in capsules, liquids, and tablets, determine downstream manufacturing, regulatory, and distribution implications. By synthesizing these dimensions with regional realities across the Americas, Europe Middle East & Africa, and Asia-Pacific and by targeting end users from ambulatory care centers to homecare settings and specialty clinics, organizations can craft resilient strategies that improve patient outcomes and operational performance. The path forward favors integrated, evidence-driven approaches that balance innovation with pragmatic commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pulmonary Drugs Market, by Product Type

  • 8.1. Biologics
  • 8.2. Bronchodilators
  • 8.3. Combination Therapies
  • 8.4. Inhaled Corticosteroids
    • 8.4.1. Beclomethasone
    • 8.4.2. Budesonide
    • 8.4.3. Fluticasone

9. Pulmonary Drugs Market, by Route Of Administration

  • 9.1. Inhalation
    • 9.1.1. Dry Powder Inhalers
    • 9.1.2. Metered Dose Inhalers
    • 9.1.3. Nebulizers
  • 9.2. Injection
    • 9.2.1. Prefilled Syringes
    • 9.2.2. Vials
  • 9.3. Oral
    • 9.3.1. Capsules
    • 9.3.2. Liquids
    • 9.3.3. Tablets

10. Pulmonary Drugs Market, by Distribution Channel

  • 10.1. Offline Pharmacies
  • 10.2. Online Pharmacies

11. Pulmonary Drugs Market, by Indication

  • 11.1. Asthma
  • 11.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 11.3. Cystic Fibrosis
  • 11.4. Interstitial Lung Disease
  • 11.5. Pulmonary Fibrosis
  • 11.6. Pulmonary Hypertension
  • 11.7. Respiratory Infections

12. Pulmonary Drugs Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Homecare Settings
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Pulmonary Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pulmonary Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pulmonary Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pulmonary Drugs Market

17. China Pulmonary Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Boehringer Ingelheim International GmbH
  • 18.8. Chiesi Farmaceutici S.p.A.
  • 18.9. Cipla Limited
  • 18.10. Dr. Reddy's Laboratories Limited
  • 18.11. F. Hoffmann-La Roche Ltd
  • 18.12. GlaxoSmithKline plc
  • 18.13. Glenmark Pharmaceuticals Limited
  • 18.14. Insmed Incorporated
  • 18.15. Lupin Limited
  • 18.16. Merck & Co., Inc.
  • 18.17. Novartis AG
  • 18.18. Pfizer Inc.
  • 18.19. Sanofi S.A.
  • 18.20. Sun Pharmaceutical Industries Limited
  • 18.21. Teva Pharmaceutical Industries Ltd.
  • 18.22. Theravance Biopharma, Inc.
  • 18.23. Vertex Pharmaceuticals Incorporated
  • 18.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BECLOMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY FLUTICASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PULMONARY DRUGS MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PULMONARY DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PULMONARY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PULMONARY DRUGS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PULMONARY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PULMONARY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INTERSTITIAL LUNG DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. GCC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 231. G7 PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 233. G7 PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. G7 PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. G7 PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. NATO PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 243. NATO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. NATO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)